A Phase I Study to Evaluate the PK and PD Profiles of GZR102 Injection Versus GZR4 Injection and GZR18 Injection Given Separately in Chinese Adult Overweight Subjects

Phase 1

Not yet recruiting

• Conditions: Type 2 Diabetes
• Interventions: Drug: GZR102 injection; Drug: GZR18 injection; Drug: GZR4 injection

• Registration Number: NCT06974487
• Lead Sponsor: Gan & Lee Pharmaceuticals.

Brief Summary

This trial is a randomized, double-blind, three-period crossover Phase I Clinical Study conducted in Chinese adult overweight subjects to evaluate the safety, tolerability, PK and PD profiles of a single dose of GZR102 injection versus GZR4 injection and GZR18 injection given separately.

Subjects undergo a screening phase of up to 3 weeks (D-21 to D-3). Eligible subjects are randomized in a 1:1:1:1:1:1 ratio into six dosing sequences, receiving single doses of GZR102 injection, GZR4 injection, and GZR18 injection across 3 cycles. A washout period of at least 1 week separates each cycle.

Detailed Description

Not available

Study Timeline

• Status Verified: 2025-04
• Study First Submitted: 2025-04-28
• Study First Submitted QC: 2025-05-07
• Last Update Submitted: 2025-05-07
• Study Start: 2025-05-08
• Study First Posted: 2025-05-16
• Last Update Posted: 2025-05-16
• Primary Completion: 2025-09-30
• Study Completion: 2025-09-30

Recruitment & Eligibility

• Status: NOT_YET_RECRUITING
• Sex: All
• Target Recruitment: 30

Inclusion Criteria

• 1. Subjects sign the Informed Consent Form (ICF) before the study, fully understand the contents, process and possible adverse reactions of the study, and be able to follow the contraindications and restrictions specified in this protocol.

  2. Subjects (male or female) age 18-60 years old (inclusive) at the time of signing ICF.

  3. Body weight ≥ 60 kg, body mass index (BMI) ≥ 24 kg/m2 and < 28 kg/m2 at screening.

  4. No birth plan from the signing of ICF to 8 weeks after the last dose, willingness to use effective methods of contraception, and no plan for sperm donation. Females of childbearing potential must not be lactating and must have negative results of blood pregnancy tests at screening and predose.

Exclusion Criteria

• 1. History of drug abuse prior to screening; or positive results for drug abuse at screening.

  2. History of alcohol abuse defined as an average alcohol intake of more than 14 units per week (1 standard unit = 360 mL of beer or 150 mL of 12% wine or 45 mL of 40% spirits) within 6 months prior to screening.

  3. Subjects who smoked > 5 cigarettes/day within 3 months prior to screening or who cannot stop using any tobacco products during the study.

  4. Subjects with a history of allergy to ≥ 2 drugs, or known hypersensitivity or intolerance to the IMP or similar products and their excipients.

  5. Presence of any suspected and/or definitively diagnosed malignancy at screening; or patients diagnosed with other malignancies within 5 years; 6. Previous or current medical history of cardiovascular, hematological, respiratory, digestive, urinary, endocrine/metabolic, neurological, or psychiatric disorders that, in the investigator's judgment, may affect the study outcomes.

  6. History of acute or chronic pancreatitis, biliary/gallbladder diseases , or pancreatic injury.

  7. Major surgery (including but not limited to procedures requiring general anesthesia) within 3 months prior to screening; or history of organ transplantation (except corneal transplantation performed more than 4 months prior to screening); or incomplete recovery from illness, trauma, or surgery at screening (e.g., significant impairment in daily living or working capacity compared to pre-illness/injury/surgery status); or planned surgery during the study period.

  8. Blood donation or significant blood loss (> 400 mL), or blood transfusion in the 3 months prior to screening.

  9. Presence of any clinically significant abnormalities in 12-lead electrocardiogram, vital signs (blood pressure, respiration, pulse rate, body temperature), physical examination, imaging examination, or laboratory tests (hematology, urinalysis, blood chemistry, coagulation function, serum amylase, serum lipase, calcitonin) as determined by the investigator at screening..

  10. Positive screening results for hepatitis B surface antigen (HBsAg), hepatitis C virus (HCV) antibody, human immunodeficiency virus (HIV) antibody, or treponema pallidum antibody infection at screening.

  11. History of organ transplantation, or acquired or congenital immune system disorders.

  12. Participation in a clinical study of another investigational medicinal product (IMP), surgery, or device within 3 months before screening, or within 5 half-lives of the previous IMP (whichever is longer). Or plan to participate in another clinical study of an IMP, surgery, or device before completing all scheduled assessments in the clinical study.

  13. Subjects who have used GLP-1 receptor agonists or drugs with the mechanism of action of GLP-1R agonists.

  14. Subjects who are allergic to any food or have specific dietary requirements and cannot adhere to a standardized diet.

  15. History of needle or blood phobia, or difficulty with blood collection; or inability/unwillingness to undergo repeated venipuncture.

  16. Subjects who were considered not suitable for the clinical study due to other reasons at the discretion of the investigator.

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: CROSSOVER

Arm && Interventions

Group	Intervention	Description
GZR102 injection	GZR102 injection	Participants will get a single dose of GZR102 injection （fixed-ratio combination of GZR4 and GZR18）.
GZR4 injection	GZR18 injection	Participants will get a single dose of GZR4 injection
GZR18 injection	GZR4 injection	Participants will get a single dose of GZR18 injection

Primary Outcome Measures

Name	Time	Method
AUC0-t	Day 36 (end of period)	Area under the plasma concentration-time curve at 0 h to last observation time-point after a single dose.

Secondary Outcome Measures

Name	Time	Method
AUC0-inf	Day 36 (end of period)	Area under the plasma concentration-time curve at 0 h to infinity after a single dose.
TEAEs	Day 36 (end of period)	Treatment-emergent adverse events in terms of number of subject
Hypoglycemia	Day 36 (end of period)	Number of subjects, number of events and incidence of treatment-emergent hypoglycemia.
Immunogenicity	Day 36 (end of period)	Including anti-drug antibody (ADA) and neutralizing antibody (NAb).
Cmax	Day 36 (end of period)	Maximum plasma concentration

Trial Locations

Locations (1)

Study site 01; 🇨🇳 Beijing, China